Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Modified-Release Drug Delivery Systems: Site-Targeted

Modified-Release Drug Delivery Systems: Site-Targeted

Site-targeted drug delivery systems enhance therapeutic efficacy while minimizing systemic toxicity and treatment costs. Unlike conventional methods, these systems ensure precise drug delivery, improving bioavailability and reducing side effects. Targeted drug delivery is classified into three levels. First-order targeting directs drugs to the capillary beds of specific organs or tissues. Second-order targets specific cell types, such as tumor cells, using receptor-mediated interactions.

Site-Targeted Drug Delivery Systems: Polymeric Carriers

Site-Targeted Drug Delivery Systems: Polymeric Carriers

Polymeric carriers enhance targeted drug delivery by increasing efficacy while minimizing off-target effects. These carriers comprise a biodegradable polymeric backbone integrated with functional elements that enable targeting, improve physicochemical properties, and regulate drug release.Targeting MechanismsThe targeting ability of polymeric carriers is mediated by a homing device, which is a molecular recognition component designed to selectively bind to specific tissues or cells. Monoclonal...

Modified-Release Drug Delivery Systems: Rate-Programmed II

Modified-Release Drug Delivery Systems: Rate-Programmed II

Rate-programmed drug delivery systems release drugs in a controlled manner to maintain therapeutic levels. Three main designs include reservoir, matrix, and hybrid systems.Reservoir systems consist of a drug core enclosed within a membrane that controls drug release. In non-swelling reservoir systems, polymers like ethyl cellulose or polymethacrylates are used. These do not hydrate in aqueous media and control release through membrane thickness, porosity, or insolubility. This type includes...

Drug Delivery Systems: Different Types

Drug Delivery Systems: Different Types

Conventional oral drug products, termed immediate-release (IR) formulations, are engineered to promptly release their active pharmaceutical ingredient (API) upon ingestion, typically in tablets or capsules. This rapid release often results in swift drug absorption and consequent pharmacodynamic effects, although the timing and intensity can vary depending on the drug's properties. Prodrugs within these formulations require metabolic conversion to activate their pharmacodynamic effects,...

Oral Drug Delivery Systems: Delayed-Release Systems

Oral Drug Delivery Systems: Delayed-Release Systems

Delayed-release drug delivery systems are specialized pharmaceutical formulations designed to postpone the release of active compounds until the drug reaches a specific region of the gastrointestinal (GI) tract, typically the intestine. These systems are essential for drugs that may cause gastric irritation, are unstable in acidic environments, or need to exert therapeutic effects locally in the intestinal or colonic regions.The core feature of delayed-release systems is the use of enteric...

Oral Drug Delivery Systems: Continuous-Release Systems

Oral Drug Delivery Systems: Continuous-Release Systems

Continuous-release drug delivery systems offer a strategic approach to maintaining therapeutic drug levels over extended periods following oral administration. By modulating the release rate of active pharmaceutical ingredients, these systems minimize fluctuations in plasma concentrations, which enhances clinical efficacy and reduces the need for frequent dosing. Such characteristics make them particularly advantageous in managing chronic diseases where patient adherence and stable drug...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Intracochlear PLGA implants for simultaneous controlled release of multiple drugs.

Journal of controlled release : official journal of the Controlled Release Society·2026

Same author

Release mechanisms of PLGA-based drug delivery systems: A review.

International journal of pharmaceutics: X·2025

Same author

Release mechanisms of PLGA microparticles prepared using a microfluidics device or a beaker.

International journal of pharmaceutics: X·2025

Same author

EVA implants for controlled drug delivery to the inner ear.

International journal of pharmaceutics: X·2024

Same author

In-situ forming PLGA implants: Towards less toxic solvents.

International journal of pharmaceutics·2024

Same author

Colon targeting in rats, dogs and IBD patients with species-independent film coatings.

International journal of pharmaceutics: X·2024

Search research articles

Related Experiment Video

Updated: Jun 3, 2026

Fabrication and Characterization of Colorectal Cancer Organoids from SW1222 Cell Line in Ultrashort Self-Assembling Peptide Matrix

Fabrication and Characterization of Colorectal Cancer Organoids from SW1222 Cell Line in Ultrashort Self-Assembling Peptide Matrix

Published on: May 3, 2024

Non-coated multiparticulate matrix systems for colon targeting.

S Krenzlin¹, F Siepmann, D Wils

¹Université Lille Nord de France, College of Pharmacy, France.

Drug Development and Industrial Pharmacy

|March 23, 2011

Summary

This summary is machine-generated.

Novel matrix pellets and mini tablets using Nutriose avoid film coating for colon-specific drug delivery in inflammatory bowel disease (IBD) treatment, enhancing therapeutic efficacy.

More Related Videos

Human Colonoid Monolayers to Study Interactions Between Pathogens, Commensals, and Host Intestinal Epithelium

Human Colonoid Monolayers to Study Interactions Between Pathogens, Commensals, and Host Intestinal Epithelium

Published on: April 9, 2019

Related Experiment Videos

Last Updated: Jun 3, 2026

Fabrication and Characterization of Colorectal Cancer Organoids from SW1222 Cell Line in Ultrashort Self-Assembling Peptide Matrix

Fabrication and Characterization of Colorectal Cancer Organoids from SW1222 Cell Line in Ultrashort Self-Assembling Peptide Matrix

Published on: May 3, 2024

Human Colonoid Monolayers to Study Interactions Between Pathogens, Commensals, and Host Intestinal Epithelium

Human Colonoid Monolayers to Study Interactions Between Pathogens, Commensals, and Host Intestinal Epithelium

Published on: April 9, 2019

Area of Science:

Pharmaceutical Technology
Drug Delivery Systems
Gastroenterology

Background:

Colon-specific drug delivery enhances efficacy for inflammatory bowel diseases (IBD).
Nutriose starch derivative coatings previously showed controlled 5-ASA release in the colon.
This study aimed to create drug delivery systems without a film coating step.

Purpose of the Study:

To develop Nutriose-containing matrix pellets and mini tablets for colon-specific drug delivery.
To evaluate drug release kinetics and minimize premature release in the upper gastrointestinal tract (GIT).

Main Methods:

Preparation of highly dosed matrix pellets via extrusion-spheronization.
Preparation of highly dosed mini tablets via compression.
Inclusion of various lipids and drug release testing in simulated upper GIT conditions (acidic and pH 6.8 buffers with enzymes).

Main Results:

Lipid type and preparation/curing conditions significantly influenced drug release kinetics.
Glyceryl palmitostearate-containing formulations demonstrated promising results after appropriate curing.
Premature drug release in simulated upper GIT conditions was minimized.

Conclusions:

Novel Nutriose-containing multiparticulates (pellets and mini tablets) eliminate the need for film coating.
These formulations show significant potential for site-specific drug delivery to the colon in IBD patients.